ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0403

Comparison of Immediate Post-Operative and Long-Term Outcomes in Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair
Abstract Number: 1156

Comparison of Immunological Biomarkers and Lung Histology in Patients with Elevated IL18 – Pulmonary Alveolar Proteinosis and Recurrent Macrophage Activation Syndrome (IL-18PAP-MAS) and Other Inflammatory Lung Diseases
Abstract Number: 1730

Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression
Abstract Number: 1648

Comparison of Methotrexate and Glucosamine in Primary Knee Osteoarthritis with Inflammation
Abstract Number: 1637

Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan
Abstract Number: 1868

Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Abstract Number: 0507

Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study
Abstract Number: 0797

Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
Abstract Number: 2048

Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
Abstract Number: 1871

Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthritis Caught Early Cohort
Abstract Number: 1810

Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine
Abstract Number: 2044

Complex, Dynamic Attributes of Antigen-specific T Cells in Rheumatoid Arthritis
Abstract Number: 0280

Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application
Abstract Number: 0627

Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series
Abstract Number: 1502

Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].